Report Thumbnail
Product Code LP0912003489VT
Published Date 2024/1/11
English155 PagesGlobal

Global Phage Therapy Market Growth (Status and Outlook) 2024-2030Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0912003489VT◆The Jan 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/1/11
English 155 PagesGlobal

Global Phage Therapy Market Growth (Status and Outlook) 2024-2030Pharmaceutical_LifeSciense Market



Abstract


Summary

According to our LPI (LP Information) latest study, the global Phage Therapy market size was valued at US$ 31 million in 2023. With growing demand in downstream market, the Phage Therapy is forecast to a readjusted size of US$ 101.3 million by 2030 with a CAGR of 18.3% during review period. _x000D_ The research report highlights the growth potential of the global Phage Therapy market. Phage Therapy are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Phage Therapy. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Phage Therapy market._x000D_ Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature, and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture._x000D_ The major players in global Phage Therapy market include NPO Microgen, Proteon Pharmaceuticals, Phagelux, etc. The top 3 players occupy about 25% shares of the global market. North America and Europe are main markets, they occupy about 60% of the global market. DsDNA Bacteriophage is the main type, with a share over 90%. Animal Health is the main application, which holds a share about 55%._x000D_ Key Features:_x000D_ The report on Phage Therapy market reflects various aspects and provide valuable insights into the industry._x000D_ Market Size and Growth: The research report provide an overview of the current size and growth of the Phage Therapy market. It may include historical data, market segmentation by Type (e.g., DsDNA Bacteriophage, SsDNA Bacteriophage), and regional breakdowns._x000D_ Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Phage Therapy market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs._x000D_ Competitive Landscape: The research report provides analysis of the competitive landscape within the Phage Therapy market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market._x000D_ Technological Developments: The research report can delve into the latest technological developments in the Phage Therapy industry. This include advancements in Phage Therapy technology, Phage Therapy new entrants, Phage Therapy new investment, and other innovations that are shaping the future of Phage Therapy._x000D_ Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Phage Therapy market. It includes factors influencing customer ' purchasing decisions, preferences for Phage Therapy product._x000D_ Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Phage Therapy market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Phage Therapy market. The report also evaluates the effectiveness of these policies in driving market growth._x000D_ Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Phage Therapy market. _x000D_ Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Phage Therapy industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments._x000D_ Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Phage Therapy market._x000D_ Market Segmentation:_x000D_ Phage Therapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value._x000D_ Segmentation by type_x000D_ DsDNA Bacteriophage_x000D_ SsDNA Bacteriophage_x000D_ SsRNA Bacteriophage_x000D_ Others_x000D_ Segmentation by application_x000D_ Animal Health_x000D_ Aquaculture_x000D_ Agriculture_x000D_ Food Industry_x000D_ Human Health_x000D_ Others_x000D_ This report also splits the market by region:_x000D_ Americas_x000D_ United States_x000D_ Canada_x000D_ Mexico_x000D_ Brazil_x000D_ APAC_x000D_ China_x000D_ Japan_x000D_ Korea_x000D_ Southeast Asia_x000D_ India_x000D_ Australia_x000D_ Europe_x000D_ Germany_x000D_ France_x000D_ UK_x000D_ Italy_x000D_ Russia_x000D_ Middle East & Africa_x000D_ Egypt_x000D_ South Africa_x000D_ Israel_x000D_ Turkey_x000D_ GCC Countries_x000D_ The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration._x000D_ NPO Microgen_x000D_ Proteon Pharmaceuticals_x000D_ Phagelux_x000D_ Intralytix_x000D_ Micreos_x000D_ Eliava BioPreparations_x000D_ Locus Biosciences,Inc_x000D_ Pharmex Group,LLC_x000D_ Pherecydes Pharma_x000D_ APS Biocontrol Ltd. (APS)_x000D_ Qingdao Phagepharm Bio-tech_x000D_ Fixed-Phage Limited_x000D_ Zeptometrix_x000D_ Phage International, Inc._x000D_ MicroMir_x000D_ iNtODEWORLD, Inc._x000D_ NEXTBIOTICS_x000D_ Armata Pharmaceuticals, Inc._x000D_ Innophage_x000D_ Adaptive Phage Therapeutics_x000D_ TechnoPhage_x000D_

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Phage Therapy Market Size 2019-2030
      • 2.1.2 Phage Therapy Market Size CAGR by Region 2019 VS 2023 VS 2030
    • 2.2 Phage Therapy Segment by Type
      • 2.2.1 DsDNA Bacteriophage
      • 2.2.2 SsDNA Bacteriophage
      • 2.2.3 SsRNA Bacteriophage
      • 2.2.4 Others
    • 2.3 Phage Therapy Market Size by Type
      • 2.3.1 Phage Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030)
      • 2.3.2 Global Phage Therapy Market Size Market Share by Type (2019-2024)
    • 2.4 Phage Therapy Segment by Application
      • 2.4.1 Animal Health
      • 2.4.2 Aquaculture
      • 2.4.3 Agriculture
      • 2.4.4 Food Industry
      • 2.4.5 Human Health
      • 2.4.6 Others
    • 2.5 Phage Therapy Market Size by Application
      • 2.5.1 Phage Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030)
      • 2.5.2 Global Phage Therapy Market Size Market Share by Application (2019-2024)
  • 3 Phage Therapy Market Size by Player

    • 3.1 Phage Therapy Market Size Market Share by Players
      • 3.1.1 Global Phage Therapy Revenue by Players (2019-2024)
      • 3.1.2 Global Phage Therapy Revenue Market Share by Players (2019-2024)
    • 3.2 Global Phage Therapy Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion
  • 4 Phage Therapy by Regions

    • 4.1 Phage Therapy Market Size by Regions (2019-2024)
    • 4.2 Americas Phage Therapy Market Size Growth (2019-2024)
    • 4.3 APAC Phage Therapy Market Size Growth (2019-2024)
    • 4.4 Europe Phage Therapy Market Size Growth (2019-2024)
    • 4.5 Middle East & Africa Phage Therapy Market Size Growth (2019-2024)
  • 5 Americas

    • 5.1 Americas Phage Therapy Market Size by Country (2019-2024)
    • 5.2 Americas Phage Therapy Market Size by Type (2019-2024)
    • 5.3 Americas Phage Therapy Market Size by Application (2019-2024)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Phage Therapy Market Size by Region (2019-2024)
    • 6.2 APAC Phage Therapy Market Size by Type (2019-2024)
    • 6.3 APAC Phage Therapy Market Size by Application (2019-2024)
    • 6.4 China
    • 6.5 Japan
    • 6.6 Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
  • 7 Europe

    • 7.1 Europe Phage Therapy by Country (2019-2024)
    • 7.2 Europe Phage Therapy Market Size by Type (2019-2024)
    • 7.3 Europe Phage Therapy Market Size by Application (2019-2024)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Phage Therapy by Region (2019-2024)
    • 8.2 Middle East & Africa Phage Therapy Market Size by Type (2019-2024)
    • 8.3 Middle East & Africa Phage Therapy Market Size by Application (2019-2024)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Global Phage Therapy Market Forecast

    • 10.1 Global Phage Therapy Forecast by Regions (2025-2030)
      • 10.1.1 Global Phage Therapy Forecast by Regions (2025-2030)
      • 10.1.2 Americas Phage Therapy Forecast
      • 10.1.3 APAC Phage Therapy Forecast
      • 10.1.4 Europe Phage Therapy Forecast
      • 10.1.5 Middle East & Africa Phage Therapy Forecast
    • 10.2 Americas Phage Therapy Forecast by Country (2025-2030)
      • 10.2.1 United States Phage Therapy Market Forecast
      • 10.2.2 Canada Phage Therapy Market Forecast
      • 10.2.3 Mexico Phage Therapy Market Forecast
      • 10.2.4 Brazil Phage Therapy Market Forecast
    • 10.3 APAC Phage Therapy Forecast by Region (2025-2030)
      • 10.3.1 China Phage Therapy Market Forecast
      • 10.3.2 Japan Phage Therapy Market Forecast
      • 10.3.3 Korea Phage Therapy Market Forecast
      • 10.3.4 Southeast Asia Phage Therapy Market Forecast
      • 10.3.5 India Phage Therapy Market Forecast
      • 10.3.6 Australia Phage Therapy Market Forecast
    • 10.4 Europe Phage Therapy Forecast by Country (2025-2030)
      • 10.4.1 Germany Phage Therapy Market Forecast
      • 10.4.2 France Phage Therapy Market Forecast
      • 10.4.3 UK Phage Therapy Market Forecast
      • 10.4.4 Italy Phage Therapy Market Forecast
      • 10.4.5 Russia Phage Therapy Market Forecast
    • 10.5 Middle East & Africa Phage Therapy Forecast by Region (2025-2030)
      • 10.5.1 Egypt Phage Therapy Market Forecast
      • 10.5.2 South Africa Phage Therapy Market Forecast
      • 10.5.3 Israel Phage Therapy Market Forecast
      • 10.5.4 Turkey Phage Therapy Market Forecast
      • 10.5.5 GCC Countries Phage Therapy Market Forecast
    • 10.6 Global Phage Therapy Forecast by Type (2025-2030)
    • 10.7 Global Phage Therapy Forecast by Application (2025-2030)
  • 11 Key Players Analysis

    • 11.1 NPO Microgen
      • 11.1.1 NPO Microgen Company Information
      • 11.1.2 NPO Microgen Phage Therapy Product Offered
      • 11.1.3 NPO Microgen Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.1.4 NPO Microgen Main Business Overview
      • 11.1.5 NPO Microgen Latest Developments
    • 11.2 Proteon Pharmaceuticals
      • 11.2.1 Proteon Pharmaceuticals Company Information
      • 11.2.2 Proteon Pharmaceuticals Phage Therapy Product Offered
      • 11.2.3 Proteon Pharmaceuticals Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.2.4 Proteon Pharmaceuticals Main Business Overview
      • 11.2.5 Proteon Pharmaceuticals Latest Developments
    • 11.3 Phagelux
      • 11.3.1 Phagelux Company Information
      • 11.3.2 Phagelux Phage Therapy Product Offered
      • 11.3.3 Phagelux Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.3.4 Phagelux Main Business Overview
      • 11.3.5 Phagelux Latest Developments
    • 11.4 Intralytix
      • 11.4.1 Intralytix Company Information
      • 11.4.2 Intralytix Phage Therapy Product Offered
      • 11.4.3 Intralytix Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.4.4 Intralytix Main Business Overview
      • 11.4.5 Intralytix Latest Developments
    • 11.5 Micreos
      • 11.5.1 Micreos Company Information
      • 11.5.2 Micreos Phage Therapy Product Offered
      • 11.5.3 Micreos Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.5.4 Micreos Main Business Overview
      • 11.5.5 Micreos Latest Developments
    • 11.6 Eliava BioPreparations
      • 11.6.1 Eliava BioPreparations Company Information
      • 11.6.2 Eliava BioPreparations Phage Therapy Product Offered
      • 11.6.3 Eliava BioPreparations Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.6.4 Eliava BioPreparations Main Business Overview
      • 11.6.5 Eliava BioPreparations Latest Developments
    • 11.7 Locus Biosciences,Inc
      • 11.7.1 Locus Biosciences,Inc Company Information
      • 11.7.2 Locus Biosciences,Inc Phage Therapy Product Offered
      • 11.7.3 Locus Biosciences,Inc Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.7.4 Locus Biosciences,Inc Main Business Overview
      • 11.7.5 Locus Biosciences,Inc Latest Developments
    • 11.8 Pharmex Group,LLC
      • 11.8.1 Pharmex Group,LLC Company Information
      • 11.8.2 Pharmex Group,LLC Phage Therapy Product Offered
      • 11.8.3 Pharmex Group,LLC Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.8.4 Pharmex Group,LLC Main Business Overview
      • 11.8.5 Pharmex Group,LLC Latest Developments
    • 11.9 Pherecydes Pharma
      • 11.9.1 Pherecydes Pharma Company Information
      • 11.9.2 Pherecydes Pharma Phage Therapy Product Offered
      • 11.9.3 Pherecydes Pharma Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.9.4 Pherecydes Pharma Main Business Overview
      • 11.9.5 Pherecydes Pharma Latest Developments
    • 11.10 APS Biocontrol Ltd. (APS)
      • 11.10.1 APS Biocontrol Ltd. (APS) Company Information
      • 11.10.2 APS Biocontrol Ltd. (APS) Phage Therapy Product Offered
      • 11.10.3 APS Biocontrol Ltd. (APS) Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.10.4 APS Biocontrol Ltd. (APS) Main Business Overview
      • 11.10.5 APS Biocontrol Ltd. (APS) Latest Developments
    • 11.11 Qingdao Phagepharm Bio-tech
      • 11.11.1 Qingdao Phagepharm Bio-tech Company Information
      • 11.11.2 Qingdao Phagepharm Bio-tech Phage Therapy Product Offered
      • 11.11.3 Qingdao Phagepharm Bio-tech Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.11.4 Qingdao Phagepharm Bio-tech Main Business Overview
      • 11.11.5 Qingdao Phagepharm Bio-tech Latest Developments
    • 11.12 Fixed-Phage Limited
      • 11.12.1 Fixed-Phage Limited Company Information
      • 11.12.2 Fixed-Phage Limited Phage Therapy Product Offered
      • 11.12.3 Fixed-Phage Limited Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.12.4 Fixed-Phage Limited Main Business Overview
      • 11.12.5 Fixed-Phage Limited Latest Developments
    • 11.13 Zeptometrix
      • 11.13.1 Zeptometrix Company Information
      • 11.13.2 Zeptometrix Phage Therapy Product Offered
      • 11.13.3 Zeptometrix Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.13.4 Zeptometrix Main Business Overview
      • 11.13.5 Zeptometrix Latest Developments
    • 11.14 Phage International, Inc
      • 11.14.1 Phage International, Inc. Company Information
      • 11.14.2 Phage International, Inc. Phage Therapy Product Offered
      • 11.14.3 Phage International, Inc. Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.14.4 Phage International, Inc. Main Business Overview
      • 11.14.5 Phage International, Inc. Latest Developments
    • 11.15 MicroMir
      • 11.15.1 MicroMir Company Information
      • 11.15.2 MicroMir Phage Therapy Product Offered
      • 11.15.3 MicroMir Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.15.4 MicroMir Main Business Overview
      • 11.15.5 MicroMir Latest Developments
    • 11.16 iNtODEWORLD, Inc
      • 11.16.1 iNtODEWORLD, Inc. Company Information
      • 11.16.2 iNtODEWORLD, Inc. Phage Therapy Product Offered
      • 11.16.3 iNtODEWORLD, Inc. Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.16.4 iNtODEWORLD, Inc. Main Business Overview
      • 11.16.5 iNtODEWORLD, Inc. Latest Developments
    • 11.17 NEXTBIOTICS
      • 11.17.1 NEXTBIOTICS Company Information
      • 11.17.2 NEXTBIOTICS Phage Therapy Product Offered
      • 11.17.3 NEXTBIOTICS Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.17.4 NEXTBIOTICS Main Business Overview
      • 11.17.5 NEXTBIOTICS Latest Developments
    • 11.18 Armata Pharmaceuticals, Inc
      • 11.18.1 Armata Pharmaceuticals, Inc. Company Information
      • 11.18.2 Armata Pharmaceuticals, Inc. Phage Therapy Product Offered
      • 11.18.3 Armata Pharmaceuticals, Inc. Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.18.4 Armata Pharmaceuticals, Inc. Main Business Overview
      • 11.18.5 Armata Pharmaceuticals, Inc. Latest Developments
    • 11.19 Innophage
      • 11.19.1 Innophage Company Information
      • 11.19.2 Innophage Phage Therapy Product Offered
      • 11.19.3 Innophage Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.19.4 Innophage Main Business Overview
      • 11.19.5 Innophage Latest Developments
    • 11.20 Adaptive Phage Therapeutics
      • 11.20.1 Adaptive Phage Therapeutics Company Information
      • 11.20.2 Adaptive Phage Therapeutics Phage Therapy Product Offered
      • 11.20.3 Adaptive Phage Therapeutics Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.20.4 Adaptive Phage Therapeutics Main Business Overview
      • 11.20.5 Adaptive Phage Therapeutics Latest Developments
    • 11.21 TechnoPhage
      • 11.21.1 TechnoPhage Company Information
      • 11.21.2 TechnoPhage Phage Therapy Product Offered
      • 11.21.3 TechnoPhage Phage Therapy Revenue, Gross Margin and Market Share (2019-2024)
      • 11.21.4 TechnoPhage Main Business Overview
      • 11.21.5 TechnoPhage Latest Developments
  • 12 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.
Global Phage Therapy Market Growth (Status and Outlook) 2024-2030 | Pharmaceutical_LifeSciense Market Research Report - ShareFair Markets